Saudi Arabia Diabetic Foot Ulcer Treatment Market (2025 - 2030)

Market Size & Trends

The Saudi Arabia diabetic foot ulcer treatment market size was estimated at USD 36.3 million in 2024 and is expected to grow at a CAGR of 7.06% from 2025 to 2030. Major factors contributing to the growth of Saudi Arabia diabetic foot ulcer treatment industry include, growing cases of diabetes, growing government initiatives and technological advancements in wound care, including bioengineered skin substitutes, negative pressure wound therapy (NPWT), and others.

The rising prevalence of diabetes in Saudi Arabia has significantly heightened the risk of developing diabetic foot ulcers. According to the World Health Organization, the country is projected to be among the top five nations with the highest prevalence of type 2 diabetes mellitus by 2030. This growing burden of diabetes directly contributes to an increase in diabetes-related complications, including foot ulcers. A study published by the National Center for Biotechnology Information (NCBI) highlights that diabetic foot ulcers are the leading cause of lower limb amputations in Saudi Arabia. The risk of ulceration and subsequent amputation increases as diabetic patients age and as the duration of their condition extends, with the likelihood increasing by two to four times over time. This growing rate further necessitates effective treatment to manage diabetic foot ulcers and reduce associated complications.

Another major factor propelling the market for diabetic foot ulcer treatment in Saudi Arabia is the increasing investment in healthcare infrastructure and advanced medical technologies. The Saudi government, as part of its Vision 2030 initiative, is prioritizing healthcare advancements, leading to improved access to specialized wound care treatments. In addition, the growing presence of multinational medical device companies and collaborations with local healthcare providers are enhancing the availability of innovative treatment options. The expansion of specialized diabetes care centers and the integration of advanced therapies, such as regenerative medicine and smart wound dressings, are further driving the market’s growth.

Lifestyle changes have a significant impact on the increasing prevalence of diabetes and, in turn, the rising cases of diabetic foot ulcers in Saudi Arabia. A sedentary lifestyle, poor dietary habits, and a growing obesity rate are major contributors to the worsening of diabetes-related complications. Limited physical activity and high consumption of processed and sugar-rich foods contribute to insulin resistance, increasing the risk of type 2 diabetes and its associated conditions, including foot ulcers. As a result, the need for effective diabetic foot ulcer treatments is growing, fueling the demand for advanced wound care solutions in the country.

Market Concentration & Characteristics

The Saudi Arabia diabetic foot ulcer treatment industry growth stage is high, driven by rising prevalence of diabetes, increasing government healthcare investments, advancements in wound care technologies, and growing awareness about early diagnosis and treatment are fueling market expansion. In addition, the presence of multinational healthcare companies, the development of specialized diabetes care centers, and the integration of innovative treatment solutions, such as regenerative medicine and smart wound dressings, are further accelerating industry growth. With Saudi Arabia’s Vision 2030 initiative prioritizing healthcare improvements, the market is expected to continue expanding rapidly in the coming years.

The degree of innovation in Saudi Arabia diabetic foot ulcer treatment industry is increasing significantly, driven by advancements in medical technology, government support, and the growing demand for effective wound care solutions. Advanced treatments such as bioengineered skin substitutes, negative pressure wound therapy (NPWT), and hyperbaric oxygen therapy (HBOT) are becoming more widely available. In addition, the integration of artificial intelligence (AI) and telemedicine in diabetic wound management is enhancing early diagnosis and personalized treatment plans.

Companies that manufacture diabetic foot ulcer treatment products are undertaking merger and acquisition activities. This strategic approach seeks to improve technological capabilities, expand industry reach, and maintain competitiveness. For instance, in October 2024, Mölnlycke Health Care has announced a research collaboration with Transdiagen (TDG), a precision medicine company focused on developing drugs and diagnostics for chronic wound healing and tissue regeneration.

Regulations in Saudi Arabia play a crucial role in shaping the diabetic foot ulcer treatment industry by ensuring high standards of patient care, product safety, and market accessibility. The Saudi Food and Drug Authority (SFDA) oversees the approval and regulation of medical devices, pharmaceuticals, and advanced wound care solutions, ensuring compliance with stringent quality and safety requirements.

Manufacturers are actively pursuing product approvals from government agencies to remain competitive in the industry. In Saudi Arabia, regulatory approval from the Saudi Food and Drug Authority (SFDA) is crucial for launching medical devices, pharmaceuticals, and advanced wound care products.

The geographical presence of manufacturers has been growing, with companies expanding their operations. For instance, in January 2025, B. Braun established its regional headquarters, B. Braun Al-Arabia LLC, in Riyadh. This strategic move contributes to the growth of the Saudi Arabian diabetic foot ulcer treatment industry by enhancing the accessibility of advanced wound care solutions and increasing local partnerships, ultimately improving patient outcomes and driving market expansion.

Treatment Insights

The alginate dressings segment held 30.4% of the country market share in 2024, accounting for the largest proportion of the market, this segment is also expected to grow at a fastest CAGR over the forecast period. This dominance is largely due to its widespread adoption in wound care management. Alginate dressings are highly valued for their superior absorbent properties, making them particularly effective for treating moderate to heavily exuding wounds, such as diabetic foot ulcers.

The foam dressing segment is also expected to grow at a significant CAGR over the forecast period, driven by its increasing adoption in diabetic foot ulcer management. Foam dressings are highly effective in absorbing wound exudate while maintaining a moist healing environment, which is essential for faster recovery and infection prevention. Their cushioning properties provide additional comfort and protection, making them a preferred choice among healthcare professionals. Moreover, advancements in foam dressing technology, including antimicrobial and silicone-coated variants, are enhancing their effectiveness. The rising prevalence of diabetes, coupled with increasing investments in advanced wound care solutions in Saudi Arabia, is expected to further fuel the growth of this segment

Ulcer Type Insights

The neuro-ischemic ulcers segment held 52.4% of the market share in 2024 and is also expected to grow at the fastest rate over the forecast period 2025 to 2030. Neuro-ischemic ulcers, which result from a combination of neuropathy and poor blood circulation, are particularly challenging to treat due to their high risk of infection and slow healing process. The rising prevalence of diabetes and associated complications has significantly increased the demand for specialized treatments targeting these ulcers. Advancements in wound care technologies, such as bioengineered skin substitutes, negative pressure wound therapy (NPWT), have contributed to the segment’s growth. In addition, increased awareness among healthcare professionals and patients about early diagnosis and treatment options has further driven demand for neuro-ischemic ulcer management solutions.

The neuropathic ulcers segment is also expected to grow over the forecast period. Neuropathic ulcers develop due to nerve damage, leading to a loss of sensation in the feet, making patients more prone to unnoticed injuries and prolonged wound healing. The rising awareness of diabetic foot care, advancements in wound healing technologies, and the growing adoption of innovative treatment options such as bioengineered skin substitutes and advanced wound dressings are contributing to the segment's expansion. In addition, government initiatives and increased healthcare investments aimed at improving diabetes management are expected to further support the growth of the neuropathic ulcers segment.

End-use Insights

The homecare segment accounted for the largest market share of 50.8% in 2024 and is further expected to grow at a fastest CAGR over the forecast period. This growth is driven by the increasing preference for home-based wound care, particularly among elderly and diabetic patients who require long-term management of diabetic foot ulcers. The rising availability of advanced wound care products, has further supported the shift toward homecare treatment. In addition, advancements in telemedicine and remote patient monitoring have enhanced accessibility to expert guidance, reducing the need for frequent hospital visits.

The hospital segment also held a significant market share in 2024. Hospitals provide a comprehensive range of treatment options for diabetic foot ulcers, including surgical interventions, debridement procedures, negative pressure wound therapy (NPWT), and hyperbaric oxygen therapy (HBOT). The presence of multidisciplinary teams, including endocrinologists, vascular surgeons, and wound care specialists, ensures effective management of complex cases. In addition, hospitals play a crucial role in handling severe ulcer complications, such as infections and amputations, which require immediate medical attention. The growing prevalence of diabetes-related foot complications and increasing investments in healthcare infrastructure in Saudi Arabia are expected to further support the hospital segment's growth.

Key Saudi Arabia Diabetic Foot Ulcer Treatment Company Insights

Key players operating in the Saudi Arabia diabetic foot ulcer treatment industry are focused on product innovation, regulatory compliance, and strategic collaborations to strengthen their market position. They are investing in advanced wound care technologies, seeking SFDA approvals, and expanding distribution networks to enhance product accessibility. In addition, partnerships with healthcare institutions and the integration of digital health solutions, such as telemedicine and AI-driven wound assessments, are further driving market growth and improving patient outcomes.

Recent Developments

• In February 2024, Mölnlycke Health Care announced that it has entered into an agreement to acquire P.G.F. Industry Solutions GmbH, an Austrian manufacturer known for its Granudacyn wound cleansing and moisturizing solutions.

• In May 2023, Smith+Nephew announced that its PICO Single Use Negative Pressure Wound Therapy Systems have been awarded an Innovative Technology contract by Vizient, Inc., the largest member-driven healthcare performance improvement company in the United States.

• In January 2023, Convatec announced the launch of ConvaFoam, an advanced foam dressing designed to meet the needs of healthcare providers and their patients. ConvaFoam is versatile, suitable for a wide range of wound types at any stage of the healing process, making it an ideal choice for effective wound management and skin protection.

Saudi Arabia Diabetic Foot Ulcer Treatment Market